Is Red Ginseng Fatigue Randomized Trial safe?

Updated October 2026

Quick Answer

Red Ginseng Fatigue Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: 1 2 3 Hyperlipidemia, a prevalent metabolic disorder characterized by elevated serum lipids including total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), alongside reduced high-density lipoprotein cholesterol (HDL-C), is a primary driver of atherosclerosis and cardiovascular diseases [].

Key Takeaways

  • 011 2 3 Hyperlipidemia, a prevalent metabolic disorder characterized by elevated serum lipids including total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), alongside reduced high-density lipoprotein cholesterol (HDL-C), is a primary driver of atherosclerosis and cardiovascular diseases []. [Zheng Yannan (2026)]
  • 02Current first-line pharmacotherapies—such as statins and fibrates—effectively lower lipid levels but are associated with side effects including myopathy, hepatic toxicity, and gastrointestinal discomfort []. [Zheng Yannan (2026)]
  • 03As a result, patients need continuous medication to maintain normal lipid levels, which may lead to drug tolerance and reduced efficacy over time. [Zheng Yannan (2026)]
  • 04While generally considered safe, it has been associated with cardiovascular side effects, including arrhythmias. [Çağlar SO (2025)]
The current Migaku evidence database contains 2 reusable source documents for Red Ginseng Fatigue Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - 1 2 3 Hyperlipidemia, a prevalent metabolic disorder characterized by elevated serum lipids including total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), alongside reduced high-density lipoprotein cholesterol (HDL-C), is a primary driver of atherosclerosis and cardiovascular diseases []. [Zheng Yannan (2026); evidence level 4] - Current first-line pharmacotherapies—such as statins and fibrates—effectively lower lipid levels but are associated with side effects including myopathy, hepatic toxicity, and gastrointestinal discomfort []. [Zheng Yannan (2026); evidence level 4] - As a result, patients need continuous medication to maintain normal lipid levels, which may lead to drug tolerance and reduced efficacy over time. [Zheng Yannan (2026); evidence level 4] - While generally considered safe, it has been associated with cardiovascular side effects, including arrhythmias. [Çağlar SO (2025); evidence level 4] - However, none of the reports in the literature have described new-onset atrial fibrillation (AF) associated with ginseng in a young, healthy patient, as in our case. [Çağlar SO (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Korean red ginseng extract ameliorates high-fat diet-induced hyperlipidemia by modulating the gut microbiota-liver metabolic axis
  2. The Paradoxical Pro-Arrhythmic Effect of Ginseng: A Case of Atrial Fibrillation in A Healthy Adult.